Trials & Filings

Durata Files NDA for Dalbavancin

Treatment covers ABSSSI

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Durata Therapeutics has submitted an NDA to the FDA seeking approval for dalbavancin for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including MRSA (methicillin resistant Staphylococcus aureus). The submission is based on the entire data set from Durata Therapeutics’ clinical development program, including positive results from two Phase III trials DISCOVER 1 and DISCOVER 2, as well as a pre...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters